197 related articles for article (PubMed ID: 38100020)
1. Liver-Directed Therapy for Neuroendocrine Tumor Metastases in the Era of Peptide Receptor Radionuclide Therapy.
Rabei R; Fidelman N
Curr Treat Options Oncol; 2023 Dec; 24(12):1994-2004. PubMed ID: 38100020
[TBL] [Abstract][Full Text] [Related]
2. The Landmark Series: Neuroendocrine Tumor Liver Metastases.
Gangi A; Howe JR
Ann Surg Oncol; 2020 Sep; 27(9):3270-3280. PubMed ID: 32632880
[TBL] [Abstract][Full Text] [Related]
3. Radioembolization with
Braat AJAT; Ahmadzadehfar H; Kappadath SC; Stothers CL; Frilling A; Deroose CM; Flamen P; Brown DB; Sze DY; Mahvash A; Lam MGEH
Cardiovasc Intervent Radiol; 2020 Feb; 43(2):246-253. PubMed ID: 31646375
[TBL] [Abstract][Full Text] [Related]
4. Interventional Liver-Directed Therapy for Neuroendocrine Metastases: Current Status and Future Directions.
D'Souza D; Golzarian J; Young S
Curr Treat Options Oncol; 2020 May; 21(6):52. PubMed ID: 32447461
[TBL] [Abstract][Full Text] [Related]
5. Arterial therapies of non-colorectal cancer metastases to the liver (from chemoembolization to radioembolization).
Hoffmann RT; Paprottka P; Jakobs TF; Trumm CG; Reiser MF
Abdom Imaging; 2011 Dec; 36(6):671-6. PubMed ID: 21584635
[TBL] [Abstract][Full Text] [Related]
6. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors.
Fiore F; Del Prete M; Franco R; Marotta V; Ramundo V; Marciello F; Di Sarno A; Carratù AC; de Luca di Roseto C; Colao A; Faggiano A
Endocrine; 2014 Sep; 47(1):177-82. PubMed ID: 24385266
[TBL] [Abstract][Full Text] [Related]
7. Intraarterial Peptide Receptor Radionuclide Therapy Using
Lawhn-Heath C; Fidelman N; Chee B; Jivan S; Armstrong E; Zhang L; Lindsay S; Bergsland EK; Hope TA
J Nucl Med; 2021 Feb; 62(2):221-227. PubMed ID: 32513903
[TBL] [Abstract][Full Text] [Related]
8. Liver-Directed Therapies for Neuroendocrine Neoplasms.
Clift AK; Frilling A
Curr Oncol Rep; 2021 Mar; 23(4):44. PubMed ID: 33721122
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization for liver metastases of a pancreatic neuroendocrine neoplasm: a single-center experience.
Nanno Y; Toyama H; Ueshima E; Sofue K; Matsumoto I; Ishida J; Urade T; Fukushima K; Gon H; Tsugawa D; Komatsu S; Kuramitsu K; Goto T; Asari S; Yanagimoto H; Kido M; Ajiki T; Fukumoto T
Surg Today; 2023 Dec; 53(12):1396-1400. PubMed ID: 37355500
[TBL] [Abstract][Full Text] [Related]
10. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy.
Ezziddin S; Meyer C; Kahancova S; Haslerud T; Willinek W; Wilhelm K; Biersack HJ; Ahmadzadehfar H
J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059
[TBL] [Abstract][Full Text] [Related]
11. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases.
Tomozawa Y; Jahangiri Y; Pathak P; Kolbeck KJ; Schenning RC; Kaufman JA; Farsad K
J Vasc Interv Radiol; 2018 Jun; 29(6):858-865. PubMed ID: 29724520
[TBL] [Abstract][Full Text] [Related]
13. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
[TBL] [Abstract][Full Text] [Related]
14. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
15. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference.
Kennedy A; Bester L; Salem R; Sharma RA; Parks RW; Ruszniewski P;
HPB (Oxford); 2015 Jan; 17(1):29-37. PubMed ID: 25186181
[TBL] [Abstract][Full Text] [Related]
16. Surgery, Liver Directed Therapy and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor Liver Metastases.
Ngongoni R; Visser B
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291892
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.
Rostambeigi N; Dekarske AS; Austin EE; Golzarian J; Cressman EN
J Vasc Interv Radiol; 2014 Jul; 25(7):1075-84. PubMed ID: 24861664
[TBL] [Abstract][Full Text] [Related]
18. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
[TBL] [Abstract][Full Text] [Related]
19. Radioembolization Versus Chemoembolization for Neuroendocrine Metastases.
Padia SA
J Vasc Interv Radiol; 2021 Mar; 32(3):482-483. PubMed ID: 33376030
[No Abstract] [Full Text] [Related]
20. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
